$KPTI has been mentioned 4 times over the past 12 months by 2 distinct FinTwit voices, with the first mention appearing on 2026-02-13. The biotech-focused voice @jacobplieth (@jacobplieth) accounts for 3 of these mentions, while @adamfeuerstein (@adamfeuerstein ✡️) contributed 1 mention. Discussion centered on clinical trial data and conference presentation strategies, with activity spanning from March through April 2026.

The most recent mentions in late April 2026 focused on $KPTI's embargo discipline ahead of the #ASCO26 conference and what clinical data remained unreleased. An earlier March 2026 mention from @adamfeuerstein addressed specific trial outcomes for selinexor in myelofibrosis, noting the drug's performance metrics on certain endpoints and tolerability profile.